Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised phase III study of nivolumab versus chemotherapy in first-line treatment of PS 2 or elderly patients with advanced non-small cell lung cancer
2016-001063-36Phase 3Active
- Sponsor
- CHU Rennes
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CHU Rennes. Primary endpoint: Overall survival. Started Jun 2016; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-001063-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001063-36.